Evidence map›Paper›PMID 25165986›Full record

ArticlePloS one2014

Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide.

Mathias Gehrmann, Stefan Stangl, Gemma A Foulds, Rupert Oellinger, Stephanie Breuninger, Roland Rad, Alan G Pockley, Gabriele Multhoff

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus.European journal of nuclear medicine and molecular imaging · 2022
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Role of membrane Hsp70 in radiation sensitivity of tumor cells.Radiation oncology (London, England) · 2015
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mathias GehrmannDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Stefan StanglDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Gemma A FouldsJohn van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom.
Rupert OellingerMedical Department II, Translational Gastroenterological Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Stephanie BreuningerDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Roland RadMedical Department II, Translational Gastroenterological Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Alan G PockleyJohn van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom.
Gabriele MulthoffDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Clinical Cooperation Group (CCG) ''Innate Immunity in Tumor Biology'', Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt, Munich, Germany.
Technical University of Munich · DEKlinikum rechts der Isar · DENottingham Trent University · GB

Funding

Wellcome TrustWellcome Trust 084399
6 · The paper itself

Abstract

backgroundWe have previously used a unique mouse monoclonal antibody cmHsp70.1 to demonstrate the selective presence of a membrane-bound form of Hsp70 (memHsp70) on a variety of leukemia cells and on single cell suspensions derived from solid tumors of different entities, but not on non-transformed cells or cells from corresponding 'healthy' tissue. This antibody can be used to image tumors in vivo and target them for antibody-dependent cellular cytotoxicity. Tumor-specific expression of memHsp70 therefore has the potential to be exploited for theranostic purposes. Given the advantages of peptides as imaging and targeting agents, this study assessed whether a 14-mer tumor penetrating peptide (TPP; TKDNNLLGRFELSG), the sequence of which is derived from the oligomerization domain of Hsp70 which is expressed on the cell surface of tumor cells, can also be used for targeting membrane Hsp70 positive (memHsp70+) tumor cells, in vitro. METHODOLOGY/PRINCIPAL

findingsThe specificity of carboxy-fluorescein (CF-) labeled TPP (TPP) to Hsp70 was proven in an Hsp70 knockout mammary tumor cell system. TPP specifically binds to different memHsp70+ mouse and human tumor cell lines and is rapidly taken up via endosomes. Two to four-fold higher levels of CF-labeled TPP were detected in MCF7 (82% memHsp70+) and MDA-MB-231 (75% memHsp70+) cells compared to T47D cells (29% memHsp70+) that exhibit a lower Hsp70 membrane positivity. After 90 min incubation, TPP co-localized with mitochondrial membranes in memHsp70+ tumors. Although there was no evidence that any given vesicle population was specifically localized, fluorophore-labeled cmHsp70.1 antibody and TPP preferentially accumulated in the proximity of the adherent surface of cultured cells. These findings suggest a potential association between membrane Hsp70 expression and cytoskeletal elements that are involved in adherence, the establishment of intercellular synapses and/or membrane reorganization. CONCLUSIONS/SIGNIFICANCE: This study demonstrates the specific binding and rapid internalization of TPP by tumor cells with a memHsp70+ phenotype. TPP might therefore have potential for targeting and imaging the large proportion of tumors (∼50%) that express memHsp70.

Indexed as

AnimalsAntibodies, MonoclonalCell Line, TumorCell MembraneEndosomesHSP70 Heat-Shock ProteinsHumansMiceProtein BindingAntibodies, MonoclonalHSP70 Heat-Shock Proteins

Identifiers

PMID25165986
PMCPMC4148261
OpenAlexW2081819466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.